- Home
- MIRM vs ALHC Comparison
MIRM vs ALHC Comparison
Compare MIRM & ALHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- ALHC
- Stock Information
- Founded
- MIRM 2018
- ALHC 2013
- Country
- MIRM United States
- ALHC United States
- Employees
- MIRM N/A
- ALHC N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- ALHC Medical Specialities
- Sector
- MIRM Health Care
- ALHC Health Care
- Exchange
- MIRM Nasdaq
- ALHC Nasdaq
- Market Cap
- MIRM 2.5B
- ALHC 2.9B
- IPO Year
- MIRM 2019
- ALHC 2021
- Fundamental
- Price
- MIRM $52.17
- ALHC $11.64
- Analyst Decision
- MIRM Strong Buy
- ALHC Buy
- Analyst Count
- MIRM 9
- ALHC 11
- Target Price
- MIRM $66.22
- ALHC $17.45
- AVG Volume (30 Days)
- MIRM 413.0K
- ALHC 3.1M
- Earning Date
- MIRM 08-06-2025
- ALHC 07-30-2025
- Dividend Yield
- MIRM N/A
- ALHC N/A
- EPS Growth
- MIRM N/A
- ALHC N/A
- EPS
- MIRM N/A
- ALHC N/A
- Revenue
- MIRM $379,251,000.00
- ALHC $3,001,892,000.00
- Revenue This Year
- MIRM $35.83
- ALHC $43.40
- Revenue Next Year
- MIRM $16.83
- ALHC $26.46
- P/E Ratio
- MIRM N/A
- ALHC N/A
- Revenue Growth
- MIRM 69.31
- ALHC 49.12
- 52 Week Low
- MIRM $36.20
- ALHC $7.92
- 52 Week High
- MIRM $54.78
- ALHC $21.06
- Technical
- Relative Strength Index (RSI)
- MIRM 56.47
- ALHC 26.02
- Support Level
- MIRM $50.96
- ALHC $11.69
- Resistance Level
- MIRM $53.59
- ALHC $12.68
- Average True Range (ATR)
- MIRM 1.63
- ALHC 0.54
- MACD
- MIRM -0.17
- ALHC -0.11
- Stochastic Oscillator
- MIRM 53.06
- ALHC 0.60
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About ALHC Alignment Healthcare Inc.
Alignment Healthcare Inc is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors through Medicare Advantage plans. These plans are marketed and sold direct-to-consumer, allowing seniors to select the manner in which customers receive healthcare coverage and services on an annual basis. The company combines a technology platform and clinical model for more effective health outcomes.